AstraZeneca announces that the efficacy rating of its COVID-19 vaccine candidate has been lowered to 76%, following new analyses of the trial run in the United States. Earlier in the week, the company had been criticized for advertising its vaccine with a 79% efficacy rating using what critics claimed was outdated data.